ENDLOS-TURBO PUT - VERTEX PHARMACEUTICALS | Market Closed - Boerse Frankfurt Warrants 01:04:45 18/05/2024 am IST | ||
| 11.8 EUR | -4.38% |
|
| Current month | -29.04% | ||
| 1 month | -29.12% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Latest news about VERTEX PHARMACEUTICALS INCORPORATED
More news
| Date | Price | Change |
|---|---|---|
| 17/24/17 | 11.95 | -3.16% |
| 16/24/16 | 12.34 | -1.99% |
| 15/24/15 | 12.59 | -6.88% |
| 14/24/14 | 13.52 | +0.52% |
| 13/24/13 | 13.45 | -3.93% |
Real-time Boerse Frankfurt Warrants
Last update May 18, 2024 at 01:04 am IST
More quotesStatic data
| Product type | Knock-Out without Stop Loss |
|---|---|
| Buy / Sell | PUT |
| Underlying | VERTEX PHARMACEUTICALS INCORPORATED |
| Issuer | DZ BANK |
| WKN | DJ7M8H |
| ISIN | DE000DJ7M8H6 |
| Date issued | 15/12/2023 |
| Strike | 573.2 $ |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 14.96 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 17.2 € |
|---|---|
| Lowest since issue | 11.39 € |
Company Profile
Vertex Pharmaceuticals Incorporated specializes in the research, development and marketing of micromolecular drugs primarily for the treatment of cancers, viral, inflammatory and auto-immune diseases.
Net sales are distributed geographically as follows: the United States (61.2%), Europe (31.5%) and other (7.3%).
Sector
-
Ratings for Vertex Pharmaceuticals Incorporated
Trading Rating
Investor Rating
ESG Refinitiv
B+
Consensus: Vertex Pharmaceuticals Incorporated
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
32
Last Close Price
445.2
USD
Average target price
462.6
USD
Spread / Average Target
+3.90%
- Stock Market
- Certificates
- Certificat
